Discover the unique perks of working in an ASC, from predictable schedules and improved collaboration to cross-training opportunities and a collaborative cultu
Press release content from Accesswire. The AP news staff was not involved in its creation.
Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
January 20, 2021 GMT
TORONTO, ON / ACCESSWIRE / January 20, 2021 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (“UA”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG”)-Unresponsive Carcinoma In-Situ (“CIS”) or are intolerant to BCG Therapy (“Study II”).
Theralase Technologies Inc.: Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
TSXV:TLT)(
OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (
PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (
UA ) has received site Institutional Review Board (
IRB ) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (
NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(
Study II ).
Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. UA is the second site to receive both central and local site IRB approval. There are 4 additional US clinical study sites that have received central IRB approval and are expected to receive loca